Prosecution Insights
Last updated: October 04, 2026

Pleechae Intellectual Property LLC

Technology area: Biotechnology & Pharmaceuticals

16 pending office actions • 8 clients • 16 examiners • 11 art units • 0 of 16 (0%) have an AI response strategy ready

Analysis

PLEECHAE Intellectual Property LLC has a portfolio of 101 career applications, in the Biotechnology & Pharmaceuticals technology area. The firm has achieved a resolved allowance rate pct of 74.19. Prosecution typically requires an avg office actions per allowance of 2.0.

The firm is currently managing 14 pending office actions. The 2.0 avg office actions per allowance provides a benchmark for the expected prosecution cycle in the Biotechnology & Pharmaceuticals field. With 101 career applications, the firm has an established record of performance. The 74.19 resolved allowance rate pct reflects its success in this sector.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=101 apps, methodology: how we score firms)

74.2%
Allowance Rate
n=101
+0.43σ
Allowance Rate (norm)
n=101
2.0
OAs to Allowance
n=23
-0.86σ
OAs to Allow (norm)
n=23
817 days
Time to Allowance
n=23
+32.0pp
Interview Lift
n=101
16.1%
RCE Rate
n=101
2.8%
Appeal Rate
n=101

Rejection Performance (% of received rejections ultimately overcome)

—
§101 Overcome
n=6 (min 20)
24.1%
§102 Overcome
n=29
24.3%
§103 Overcome
n=37
28.0%
§112 Overcome
n=25

Specialization & Scale

A61P, A61K, C12N
Top CPC Subclasses
34%
Top-3 CPC Share
n=101
0
Practitioners
n=101
—
Apps / Practitioner
n=101 (min 20)

Portfolio Summary

16
Total Pending OAs
10
Non-Final OAs
6
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

8
Hard (50%)
8
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (12%)
§103 only3 (19%)
§102 only3 (19%)
Double-patenting + other2 (12%)
Multi-statute (no §101)6 (38%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
56% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
1
Semiconductors
6% of docket
2
Mechanical / Eng
12% of docket
4
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

160 h
Manual time on pending OAs
32 h
Time saved (low, 20%)
56 h
Time saved (mid, 35%)
1.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WESTFALL, SARAH ANN 1 0.0% +0.0%
CATTUNGAL, SANJAY 1 83.5% +11.1%
HAVLIN, ROBERT H 1 51.5% +28.1%
STOYTCHEV, MARIN STOYTCHEV 1 72.0% -4.6%
MARSH, OWEN LEWIS 1 66.7% +50.0%
LEON MUNOZ, EDWIN A 1 88.4% +8.1%
BASQUILL, SEAN M 1 38.8% +21.7%
COFFA, SERGIO 1 61.1% +32.5%
TICHY, JENNIFER M.H. 1 64.9% +34.5%
NGUYEN, NGHI V 1 53.6% +50.8%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18282298 APPARATUS, METHOD AND SYSTEM FOR PROVIDING TACTILE MEDIUM CATTUNGAL, SANJAY —

Hard Cases (8)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17845493 POLYIMIDE COPOLYMER AND POLYIMIDE FILM USING THE SAME KAHN, RACHEL 1d overdue
18375599 COMPOSITION FOR ENHANCING GROWTH OF PLANTS WELLES, COLMAN THOMAS 21d
18678085 METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF MARSH, OWEN LEWIS 23d
18879387 APPARATUS AND METHOD FOR EVALUATING CEREBRAL AUTOREGULATION WESTFALL, SARAH ANN —
18720849 SMART CONTACT LENS STOYTCHEV, MARIN STOYTCHEV —
18700388 RF CONNECTOR HAVING SHIELDING STRUCTURE LEON MUNOZ, EDWIN A —
18692447 PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS BASQUILL, SEAN M —
18278468 MAGNET ASSEMBLY FOR MOBILE TERMINAL AND WIRELESS CHARGING DEVICE COMBINED THEREWITH TAYLOR, APRIL ALICIA —

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18678085 METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF MARSH, OWEN LEWIS 23d
18282298 APPARATUS, METHOD AND SYSTEM FOR PROVIDING TACTILE MEDIUM CATTUNGAL, SANJAY —
18872978 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL HAVLIN, ROBERT H —
18692447 PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS BASQUILL, SEAN M —
18580752 PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD COFFA, SERGIO —
18577427 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VASCULAR DEMENTIA TICHY, JENNIFER M.H. —
18577432 PHARMACEUTICAL COMPOSITION FOR ALLEVIATION OR TREATMENT OF CEREBRAL INFARCTION SEQUELA NGUYEN, NGHI V —

Client Portfolio (8 clients)

Top Art Units

Art UnitApps
16532
37981
16261
28721
37961
16141
16311
16121
16571
16741

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18879387 APPARATUS AND METHOD FOR EVALUATING CEREBRAL AUTOREGULATION Seoul National University Hospital WESTFALL, SARAH ANN §101§102§103§112 Non-Final OA — Pending Dec 27, 2024
18282298 APPARATUS, METHOD AND SYSTEM FOR PROVIDING TACTILE MEDIUM Seoul National University R&Db Foundation CATTUNGAL, SANJAY 3798 §102Other Non-Final OA — Pending Dec 13, 2024
18872978 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES CONTAINING DEMETHYLZEYLASTERAL Seoul National University R&Db Foundation HAVLIN, ROBERT H 1626 §102§103§112DP Non-Final OA — Pending Dec 09, 2024
18720849 SMART CONTACT LENS Opthroth Inc. STOYTCHEV, MARIN STOYTCHEV 2872 §103§112 Non-Final OA — Pending Jun 17, 2024
18678085 METHOD FOR DETECTING SIGNS OF ATRIAL FIBRILLATION IN NORMAL SINUS RHYTHM AND DEVICE THEREOF Chonnam National University Hospital MARSH, OWEN LEWIS 3796 §101§112 Final Rejection 23d Pending May 30, 2024
18700388 RF CONNECTOR HAVING SHIELDING STRUCTURE Novatech Co., Ltd. LEON MUNOZ, EDWIN A §102§103 Non-Final OA — Pending Apr 11, 2024
18692447 PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS Seoul National University R&Db Foundation BASQUILL, SEAN M 1614 §102§103 Non-Final OA — Pending Mar 15, 2024
18580752 PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD Gwangju Institute of Science and Technology COFFA, SERGIO §102 Non-Final OA — Pending Jan 19, 2024
18577427 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VASCULAR DEMENTIA Industry-University Cooperation Foundation Hanyang University TICHY, JENNIFER M.H. 1653 §103DP Non-Final OA — Pending Jan 08, 2024
18577432 PHARMACEUTICAL COMPOSITION FOR ALLEVIATION OR TREATMENT OF CEREBRAL INFARCTION SEQUELA Industry-University Cooperation Foundation Hanyang University NGUYEN, NGHI V 1653 §103 Final Rejection — Pending Jan 08, 2024
18287435 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PARKINSON'S DISEASE, AND PREPARATION METHOD THEREOF Industry Foundation Of Chonnam National University SCHUBERG, LAURA J 1631 §102 Final Rejection — Pending Oct 18, 2023
18375599 COMPOSITION FOR ENHANCING GROWTH OF PLANTS Industry Foundation Of Chonnam National University WELLES, COLMAN THOMAS 1612 §103§112 Non-Final OA 21d Pending Oct 02, 2023
18284239 COMPOSITION FOR ENHANCING PHYSIOLOGICAL EFFICACY OF LACTIC ACID BACTERIA Seoul National University R&Db Foundation LANKFORD JR, LEON B 1657 §103 Final Rejection 39d Pending Sep 26, 2023
18278468 MAGNET ASSEMBLY FOR MOBILE TERMINAL AND WIRELESS CHARGING DEVICE COMBINED THEREWITH Novatech Co., Ltd. TAYLOR, APRIL ALICIA §102§103§112 Non-Final OA — Pending Aug 23, 2023
18024819 PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Seoul National University Hospital CHANDRA, GYAN 1674 §103 Final Rejection — Pending Mar 06, 2023
17845493 POLYIMIDE COPOLYMER AND POLYIMIDE FILM USING THE SAME Jeonju University Office Of Industry-University Cooperation KAHN, RACHEL 1766 §103§112 Final Rejection 1d overdue Pending Jun 21, 2022

Managing Pleechae Intellectual Property LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month